Weekly Paclitaxel Versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study

INTRODUCTION: Treatment of recurrent platinum-resistant ovarian and peritoneal cancers represents a therapeutic challenge. The aim of this Phase III prospective study was to compare the survival benefits, objective response rate, and toxicities among patients treated by weekly paclitaxel with those...

Descripción completa

Detalles Bibliográficos
Autores principales: Osman, Mohammed A., Elkady, Mohammad S., Nasr, Khalid E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847552/
https://www.ncbi.nlm.nih.gov/pubmed/27147900
http://dx.doi.org/10.4137/CMO.S38204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847552/
https://www.ncbi.nlm.nih.gov/pubmed/27147900
http://dx.doi.org/10.4137/CMO.S38204

Ejemplares similares